Severe adverse impact on sexual functioning and fertility of bone marrow transplantation, either allogeneic or autologous, compared with consolidation chemotherapy alone: analysis of the MRC AML 10 trial.

Severe adverse impact on sexual functioning and fertility of bone marrow transplantation, either allogeneic or autologous, compared with consolidation chemotherapy alone: analysis of the MRC AML 10 trial.

BACKGROUND: Data relating to the impact of bone marrow transplantation (BMT) on sexual functioning are equivocal; some studies have shown no major impact whereas others demonstrate a significant adverse effect on sexual health in patients treated with BMT. Further clarification is required to facili...

Full description

Bibliographic Details
Main Authors:	Watson, M, Wheatley, K, Harrison, G, Zittoun, R, Gray, R, Goldstone, A, Burnett, A
Format:	Journal article
Language:	English
Published:	1999

Similar Items

The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial.
by: Burnett, A, et al.
Published: (2002)

Impact of diagnostic cytogenetics on outcome in AML: Analysis of 1,613 patients entered into the UK MRC AML 10 trial.
by: Grimwade, D, et al.
Published: (1996)

The importance of diagnostic cytogenetics in older patients with AML: Analysis of 922 patients entered into the MRC AML 11 trial.
by: Grimwade, D, et al.
Published: (1999)

Del(9q) AML: Clinical, cytological and cytogenetic characteristics and prognostic implications for patients entering the MRC AML trials.
by: Peniket, A, et al.
Published: (1999)

A simple, robust and highly predictive prognostic index for the determination of risk directed therapy in acute myeloid leukaemia (AML) derived from the United Kingdom medical research council (MRC) AML10 trial.
by: Wheatley, K, et al.
Published: (1995)

The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.
by: Grimwade, D, et al.
Published: (1998)

The presence of a FLT3 mutation in AML adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the MRC AML 10 and 12 trials.
by: Kottaridis, P, et al.
Published: (2000)

AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results from the MRC's 9th AML trial.
by: Hoyle, C, et al.
Published: (1989)

Adverse impact of bone marrow transplantation on quality of life in acute myeloid leukaemia patients; analysis of the UK Medical Research Council AML 10 Trial.
by: Watson, M, et al.
Published: (2004)

Outcome for children with relapsed acute myeloid leukaemia following initial therapy in the Medical Research Council (MRC) AML 10 trial. MRC Childhood Leukaemia Working Party.
by: Webb, D, et al.
Published: (1999)

Comparison of 1 + 5 DAT and 3 + 10 DAT followed by COAP or MAZE consolidation therapy in the treatment of acute myeloid leukemia: MRC ninth AML trial.
by: Rees, J, et al.
Published: (1987)

The role of molecular diagnosis and residual disease monitoring in APL: Results of the MRC ATRA trial.
by: Grimwade, D, et al.
Published: (1998)

The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial.
by: Grimwade, D, et al.
Published: (2001)

Erythrocyte membrane-camouflaged nanoparticles as effective and biocompatible platform: Either autologous or allogeneic erythrocyte-derived
by: Jun Dai, et al.
Published: (2022-06-01)

Favorable results of allogeneic bone marrow transplantation (BMT) for adults with Philadelphia (Ph)-chromosome-negative acute lymphoblastic leukemia (ALL) in first complete remission (CR): Results from the International ALL trial (MRC UKALL XII/ECOG E2993).
by: Rowe, J, et al.
Published: (2001)

Standard Consolidation/Maintenance Chemotherapy Is Consistently Superior to a Single Autologous Transplant for Adult Patients with Acute Lymphoblastic Leukemia: Results of the International ALL Trial (MRC UKALL XII/ECOG E2993).
by: Rowe, J, et al.
Published: (2008)

Comparison of allogeneic transplant versus chemotherapy for relapsed childhood acute lymphoblastic leukaemia in the MRC UKALL R1 trial. MRC Childhood Leukaemia Working Party.
by: Harrison, G, et al.
Published: (2000)

Detection of minimal residual disease (MRD) in APL by "real-time" RT-PCR: Analysis of cases entered into the UK MRC ATRA trial.
by: Grimwade, D, et al.
Published: (1999)

No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC/NCRI trials
by: Gale, R, et al.
Published: (2018)

In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993).
by: Goldstone, A, et al.
Published: (2008)

Del (9q) AML: clinical and cytological characteristics and prognostic implications.
by: Peniket, A, et al.
Published: (2005)

Intrathecal Transplantation of Autologous and Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells in Dogs
by: Felipe Pérez Benavides, et al.
Published: (2021-08-01)

P1313: PREDICTING OUTCOMES IN AML PATIENTS CONSOLIDATED BY AN ALLOGENEIC STEM CELL TRANSPLANTATION USING THE KNOWLEDGE BANK APPROACH
by: M. Jentzsch, et al.
Published: (2022-06-01)

Autologous Transplantation for Older Adults with AML
by: Beatrice U. Mueller, et al.
Published: (2018-09-01)

Comparison of allogeneic transplant versus chemotherapy for relapsed childhood acute lymphoblastic leukaemia in the MRC UKALL R1 trial
by: Harrison, G, et al.
Published: (2000)

Maintenance therapy for AML after allogeneic HCT
by: Rahul K. Nayak, et al.
Published: (2022-08-01)

Molecular characterization of AML‐MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC‐defining criteria, TP53 allelic state, or TP53 variant allele frequency
by: Davidson Zhao, et al.
Published: (2023-03-01)

Bridging Strategies to Allogeneic Transplant for Older AML Patients
by: Judith Hecker, et al.
Published: (2018-07-01)

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials.
by: Kottaridis, P, et al.
Published: (2001)

THE EFFICACY OF HIGH-DOSE CONSOLIDATION AND AUTOLOGOUS BONE MARROW TRANSPLANTATION IN FIRST REMISSION OF ACUTE MYELOID LEUKEMIA
by: I. A. Samorodova, et al.
Published: (2018-05-01)

Association between reproducible flow cytometric methodology for measuring multidrug resistance and remission rates in AML
by: Pallis, M, et al.
Published: (1998)

PB1864: IMPROVED LONG-TERM SURVIVAL OF ELDERLY ADULTS WITH AML RECEIVING INTENSIVE INDUCTION THERAPY FOLLOWED BY EITHER ALLOGENEIC STEM CELL TRANSPLANT OR MAINTENANCE DIFFERENTIATIVE THERAPY
by: Federica DI Biase, et al.
Published: (2023-08-01)

MRC2020: improvements to Ximdisp and the MRC image-processing programs
by: J. M. Short, et al.
Published: (2023-09-01)

Allogeneic transplant (related or unrelated donor) is the preferred treatment for adult Philadelphia chromosome positive (Ph plus) acute lymphoblastic leukaemia (ALL). Results from the international ALL trial (MRC UKALLXII/ECOG E2993).
by: Goldstone, A, et al.
Published: (2001)

P384: THE ROLE OF THE MANNOSE RECEPTOR C-TYPE 2 (MRC2) IN LEUKEMIC STEM CELL MAINTENANCE IN AML
by: M. Arnone, et al.
Published: (2022-06-01)

Value of molecular monitoring for minimal residual disease preceding autologous SCT following diagnosis of B cell acute lymphoblastic leukemia in patients treated with the MRC UKALL12 protocol.
by: Foroni, L, et al.
Published: (2005)

P1260: BIODISTRIBUTION OF LABELED AUTOLOGOUS AND ALLOGENEIC BONE MARROW MESENCHYMAL STROMAL CELLS IN RABBITS AFTER INTRAVENOUS ADMINISTRATION
by: Anastasiya Pestrikova, et al.
Published: (2023-08-01)

Successful repigmentation of vitiligo after allogeneic bone marrow transplantation for Hodgkin′s lymphoma by autologous noncultured melanocyte-keratinocyte transplantation
by: Huijuan Tang, et al.
Published: (2015-01-01)

Treatment of high risk leukaemia - Results of MRC childhood acute lymphoblastic leukaemia study MRC HR-1.
by: Kinsey, S, et al.
Published: (2002)

The Elephant in The Room: AML Relapse Post Allogeneic Hematopoietic Cell Transplantation
by: Iman Abou Dalle, et al.
Published: (2022-01-01)